(b) Revenue for Q2 2024 included intercompany revenue of $9 million prior to the spin-off of GRAIL. Non-GAAP gross margin remained flat primarily due to higher freight and duties costs related to tariffs and an (c) increase in field service costs, partially offset by lower strategic partnership revenue, that is lower margin, and a more favorable product mix. The decrease in GAAP gross margin was primarily due to a $23 million impairment of an acquired intangible asset. SAN DIEGO, July 31, 2025 /PRNewswire/ ...

公司动态 - Illumina宣布扩大临床肿瘤学产品组合 包括TSO Comprehensive测试和Pillar oncoReveal CDx新产品 [1][2] - TSO Comprehensive是首个也是唯一获得FDA批准的分布式全面基因组分析IVD试剂盒 可评估DNA和RNA [3][9] - TSO Comprehensive现已获得美国医疗保险和大多数商业健康计划的覆盖 [5] - 公司与Pillar Biosciences扩大合作 将于今年夏天开始向客户提供Pillar oncoReveal CDx [6] 产品技术 - TSO Comprehensive检测超过500个基因 帮助识别免疫肿瘤生物标志物或临床可操作生物标志物 [9] - TSO Comprehensive已获FDA批准作为CDx 用于识别可能受益于Bayer的VITRAKVI和Lilly的RETEVMO治疗的患者 [10] - Pillar oncoReveal CDx是基于二代测序的IVD试剂盒 可检测22个基因的SNVs 插入和缺失 [12] - oncoReveal CDx已获FDA批准用于识别可能受益于EGFR-TKI治疗的非小细胞肺癌患者 [12] 市场拓展 - 美国路易斯维尔大学医院成为首个向患者提供TSO Comprehensive测试的Illumina客户 [3] - TSO Comprehensive试剂盒现已在日本获得监管批准 [5] - oncoReveal CDx已获得美国医疗保险全国覆盖 覆盖超过6600万人 [6][7] - 公司将在芝加哥举行的美国临床肿瘤学会年会上展示其肿瘤分析和IVD解决方案 [1]